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Abstract
Background: Recently, heightened systemic translocation of microbial products was found in persons with chronic HIV
infection and this was linked to immune activation and CD4
+ T cell homeostasis.
Methodology: We examined here the effects of microbial Toll-like receptor (TLR) ligands on T cell activation in vitro.
Conclusions/Findings: We show that exposure to TLR ligands results in activation of memory and effector CD4
+ and CD8
+ T
cells. After exposure to each of 8 different ligands that activate TLRs 2, 3, 4, 5, 7, 8, and 9, CD8
+ T cells are activated and gain
expression of the C type lectin CD69 that may promote their retention in lymphoid tissues. In contrast, CD4
+ T cells rarely
increase CD69 expression but instead enter cell cycle. Despite activation and cell cycle entry, CD4
+ T cells divide poorly and
instead, disproportionately undergo activation-induced cell death. Systemic exposure to TLR agonists may therefore
increase immune activation, effector cell sequestration in lymphoid tissues and T cell turnover. These events may contribute
to the pathogenesis of immune dysfunction and CD4+ T cell losses in chronic infection with the human immunodeficiency
virus.
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Introduction
Microbial challenge is recognized by cells of the innate immune
system through the interactions of conserved microbial structures
with a family of type 1 transmembrane receptors called Toll-like
receptors (TLRs). To date, 10 members of the TLR family, that
differ in ligand specificities and expression patterns, have been
described in humans [1,2]. Recently, translocation of microbial
products from the gut has been implicated as important in the
pathogenesis of immune activation in chronic HIV infection [3].
Increased blood levels of the TLR4 ligand lipopolysaccharide
(LPS) have been found in chronic HIV infection and these levels
correlate directly with immune activation and inversely with CD4
+
T cell restoration after antiviral therapies. Moreover, LPS levels
were increased in the blood of pathogenic (rhesus) SIV infection
but not in non-pathogenic SIV infection of sooty mangabeys that
characteristically do not experience immune activation and high T
cell turnover during chronic infection [4]. We show here that in
vitro exposure to microbial TLR ligands promotes selective
activation and death, especially of memory and effector T cells
that may contribute to the pathogenesis of immune deficiency in
chronic HIV infection.
Results
TLR ligands can induce early activation marker
expression on CD4
+ and CD8
+ T cells
To evaluate responsiveness of T cell populations to TLR
stimulation, whole PBMCs were cultured in medium alone, or in
medium supplemented with a TLR ligand. After overnight culture
with ligands for TLR 3, 4, 5, and 9, expression of CD38 (but not
HLA-DR) was induced on both CD4
+ and CD8
+ T lymphocytes
(Figure 1)
Central memory and effector/memory CD4
+T cells enter
cell cycle while memory/effector CD8
+ T cells express
high levels of CD69 after exposure to TLR ligands
We next examined surface expression of CD69, a C type lectin
implicated in the retention of activated T cells within lymph nodes
[5,6], and intracellular expression of Ki-67, a marker of cell cycle
entry. After 7 days’ cultivation with each TLR ligand, CD8
+ T
cells were induced to express high levels of CD69, and CD4
+ T
cells entered cell cycle (Figures 2A, 2B). These two pathways of
cellular activation were relatively selective for the different T cell
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+ T cells only increased CD69
expression significantly in response to Flagellin A and poly U
stimulation and otherwise were rarely found to express CD69 at
any time after stimulation (D1, D3, D5, or D7, not shown). On the
other hand, activated CD8
+ T cells entered cell cycle less
frequently than did the activated CD4+ T cells and only in the
presence of certain ligands (PGN, poly I:C, Flagellin A,
Imiquimod, and CpG DNA) did treated cells enter cycle more
frequently than did cells cultured in medium alone. Each TLR
ligand was tested at multiple concentrations (not shown) and
results are shown using an optimal concentration for each agonist.
Interestingly, maturation phenotype predicted the magnitude of
response such that in response to most ligands, central memory
and effector memory CD4+ T cells more often entered cell cycle
than did naı ¨ve CD4+ T cells and among CD8+ T cells, effector
memory cells tended to have the greatest frequency of CD69
expression. (Figure 3A–D).
The TLR 3 ligand poly I:C can activate T cells directly and
despite expression of TLR 5, purified T cells require an
intermediary cell for activation by the TLR 5 ligand
flagellin
We were able to confirm expression of TLR-3 and TLR-5 in
circulating T lymphocytes while expression of TLR2 was not
convincing (Figure 4). Expression of these TLRs on both CD4
+
and CD8
+ phenotypically defined naı ¨ve (CD45RA
+C-
D45RO
2CCR7
+) and memory (CD45RA
2CD45RO+) T cell
subsets mirrored their expression in the unseparated T cell
populations (not shown). Exposure to the TLR 3 ligand poly I:C
could induce CD38 expression directly on purified T cells
(Figure 4B). On the other hand, while T cells within PBMC
preparations could be activated to express CD38 after exposure to
the TLR5 ligand flagellin, purified T cells were not; nor could they
be induced to express CD38 through transwell exposure to soluble
products of flagellin-stimulated PBMC (Figure 4B).
TLR ligand exposure preferentially induces CD4
+ T
lymphocyte apoptosis
TLR ligation is thought to play a role in B cell homeostasis by
promoting expansion and survival of both memory [7] and naı ¨ve
[8] B lymphocytes. We therefore examined the effects of TLR
ligands on the in vitro expansion of CD4
+ and CD8
+ T cells after
staining with CFSE (Figure 5). Despite substantial movement of
CD4
+ T cells into cycle after exposure to TLR ligands (Figure 2A),
there was little dilution of dye that would reflect cell division. In
contrast, there was substantial evidence of cell death as reflected in
Annexin V binding. As CD8
+ T cells infrequently entered cell
cycle after TLR ligation, a failure of cellular proliferation was not
surprising. Nonetheless, even among CD8
+ T cells, exposure to
TLR ligands resulted in more Annexin V binding than was seen
among cells cultured in medium alone.
Discussion
Toll-like receptors play a critical role in early recognition of
potential pathogens [2,9]. Broadly expressed by epithelial cells,
phagocytic, and antigen- presenting cells, TLRs are critical sensors
for innate immune defenses, allowing rapid detection and
responsiveness to elements expressed by a wide range of microbes.
There is increasing recognition that the innate and adaptive
defense systems are linked. Thus, TLR ligation results in
production of inflammatory cytokines and increased expression
of co-stimulatory molecules and class I and II MHC antigens,
leading to more a more effective presentation of peptides to
promote T cell activation and expansion [2,9,10]. The recent
demonstration of selected TLR RNAs and protein in T cells
suggested that these ancient receptors also may have a direct role
in the maturation or expansion of the adaptive cellular immune
response [1]. In these experiments, we therefore asked if TLR
ligand exposure could promote T cell activation. We find that even
in the absence of high affinity T cell receptor engagement, TLR
agonists can induce activation of CD4
+ and CD8
+ T lymphocytes.
Figure 1. Stimulation of peripheral blood cells by Toll-like Receptor ligands increases expression of CD38 on CD4+ and CD8+ T
lymphocytes. PBMC were cultured overnight in medium alone, or stimulated with individual TLR ligands (Poly-I:C, LPS, Flagellin, or CpG DNA) or
with plate-bound anti-CD3 antibody. Expression of CD38 and HLA-DR was monitored by flow cytometry among: (A) CD4+ T cells and (B) CD8+ T cells.
Percentages of cells expressing each marker are shown. This experiment is representative of 5.
doi:10.1371/journal.pone.0001915.g001
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+ and CD8
+ T cells show
increased surface expression of the activation-related multifunc-
tional ectoenzyme CD38 that is highly expressed on activated T
lymphocytes in HIV infection and is a strong predictor of disease
progression therein [11–14]. After longer term cultivation, CD4
+
and CD8
+ T cells showed distinctly different pathways of
activation. CD4
+ T cells were induced to enter cell cycle and
rarely expressed the C-type lectin CD69 on the cell surface. In
contrast, CD8
+ T cells were activated to express CD69, and were
less frequently induced to enter cell cycle. Importantly, among
CD4+ T cells, naı ¨ve cells were less frequently activated than were
memory and effector populations except in response to the TLR 3
ligand polyI:C that activates T cells directly. Among CD8+ T cells,
cells of the effector memory phenotype were most activated to
express CD69 by TLR agonist exposure while activation of central
memory and naı ¨ve phenotype cells was generally less dramatic
although exposure to the TLR 3 agonist polyI:C and to the TLR 7
agonist poly U resulted in substantial activation of all CD8+ T cell
maturation phenotypes.
Interestingly, despite the clear demonstration of TLR5 on
circulating T cells, purified T lymphocyte populations were not
responsive to the TLR5 ligand flagellin nor were they responsive
to soluble products of PBMC preparations in which flagellin
responses were demonstrable. Thus an intermediary contact with
a TLR 5-expressing accessory cell is likely necessary to promote T
cell activation in response to this ligand. On the other hand,
purified T cells could be activated directly in response to the TLR
3 ligand poly I:C. While it is possible that low level contamination
of these purified T cell populations with TLR-bearing accessory
cells may have contributed to the T cell activation by poly I:C, it
should be noted that these same T cell preparations were
sufficiently depleted of accessory cells to remain unaffected by
anti-CD3 stimulation. Thus, for at least one TLR ligand, poly I:C,
T cells may be activated directly; for flagellin, despite clear
expression of TLR5, T cells are not activated directly, but require
the presence of accessory cells. Thus, for some ligands like flagellin,
TLR expression on T cells is not sufficient to promote T cell
activation. Whether TLR expression is necessary for T cells to be
activated in response to TLR ligands is not clear but the very low
levels of certain TLR mRNAs and protein found among purified
T cells [1,10,15,16] and the substantial T cell activation in
response to many TLR ligands that bear poor relationships to
Figure 2. TLR ligands induce high level CD69 expression on CD8+ T cells and Ki- 67 expression in CD4+ T cells. Intracellular expression
of Ki-67 (A) and surface expression of CD69 (B) were monitored after 7 days of cell culture in medium or with the stimuli as indicated. Bars represent
means and the lines standard errors of the mean (SEM) of 15 separate experiments using PBMC of healthy controls. Black boxes=CD4+ T cells and
gray boxes=CD8+ T cells. *=nominally significantly different (p,0.05 by Wilcoxon Sign Rank test when compared to results obtained in medium
alone.
doi:10.1371/journal.pone.0001915.g002
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receptors may not be necessary for responses to certain of these
TLR agonists. .
Purified human CD4
+ T lymphocytes proliferate and secrete
cytokines in response to flagellin or R848, when a secondary signal
such as anti-CD3 or IL-2 is also provided [16]. Regulatory T cell
function is enhanced and levels of the transcriptional regulator
FOXP3 are increased after exposure to flagellin and TCR
stimulation [15]. Though direct exposure of human T cells to
LPS does not induce proliferation or cytokine secretion;
phosphorylation of p38 and Pyk-2 and altered chemotactic
responses to stromal cell derived factor 1a (SDF-1a) are
demonstrable [17]. Our studies are the first to describe the
consistent and differential responsiveness of CD4
+ and CD8
+ T
maturation subsets after stimulation with a broad panel of TLR
ligands. Activation of T cells by TLR ligands was especially
demonstrable among phenotypically defined memory or memory/
effector cells, as naı ¨ve cells were far less responsive to TLR agonist
exposure. Thus, exposure to TLR ligands at sites of microbial
invasion may selectively enhance activation of memory and
effector T cells that are concurrently engaged through their TCRs
or perhaps even via bystander cytokine costimulation.
There is increasing evidence to suggest that T cell activation by
TLR ligands also may play an important role in HIV disease
pathogenesis. Recently, RNA sequences derived from the HIV-1
genome have been shown to induce activation via interactions
with TLR 7/8 [18,19] and this interaction may activate T cell
populations indirectly [20]. Very recently, we found high levels of
bacterial LPS in the plasmas of persons with chronic HIV infection
[3]. Levels of LPS were correlated with indices of T cell activation
and with plasma levels of interferon-alpha and predicted inversely
the magnitude of CD4+ T cell restoration after application of
HAART. These findings suggest that the gut barrier to systemic
translocation of a variety of commensal microbial elements is
perturbed in chronic HIV infection as LPS does not character-
istically induce alpha interferon expression. The importance of this
model in HIV disease pathogenesis is suggested by the
demonstration that in the pathogenic (rhesus) model of SIV
infection, LPS levels were increased in infected animals, while in
the non-pathogenic (sooty mangabey) model, SIV infection did not
Figure 3. TLR ligands preferentially activate CD4+ central memory and effector memory T cells and CD8+ effector memory T cells.
Intracellular Ki-67 expression (3A, 3C) and cell surface CD69 (3B, 3D) were analyzed after 7 days’ incubation of PBMC in medium alone, or in medium
supplemented with plate bound anti-CD3 antibodies, or the indicated TLR ligand. Figures 3A and B are representative results among phenotypically
defined naı ¨ve (CD45RA
+CD45RO
2CCR7
+), central memory (CD45RA
2CD45RO
+CCR7
+), and effector memory (CD45RA
2CD45RO
+CCR7
2) CD4
+ and
CD8
+ T cells. Values represent percentages of cells staining for Ki-67 or CD69. Figures 3C and 3D reflect the mean data from 15 separate experiments.
Values nominally significantly different from medium alone values (Wilcoxon Sign Rank Test) are shown with an asterisk.
doi:10.1371/journal.pone.0001915.g003
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increases in circulating levels of bacterial DNAs in chronic HIV
infection and these bacterial DNA levels also were correlated with
indices of immune activation and cellular restoration after
application of antiviral therapies (unpublished data).
Our data may provide insights as to how systemic exposure to a
number of microbial TLR agonists drives immune activation and
disease pathogenesis in HIV infection. Secondary lymph nodes in
chronic HIV infection tend to be enriched for effector CD8+ T
cells of numerous specificities that are ordinarily relatively
excluded from these sites [21–25]. Induction of CD69 by type I
interferons has been associated with intracytoplasmic retention of
the sphingosine-1 phosphate (S1P) receptor S1P1 that facilitates
exit of activated T cells from lymphoid tissues [6]. Thus, induction
of CD69 expression by TLR ligand exposure may thereby result in
inappropriate sequestration of activated CD8+ EM T cells in
lymphoid tissue where they contribute to the lymphadenopathy
[26] and inflammatory cytokine storm that characterizes HIV
infection [24,27]. In earlier work we [28] and others [29,30] have
found high frequencies of circulating S phase CM T cells in HIV
and SIV infections respectively. These cells turn over rapidly in
untreated infection [29–32]. We show here that T cell activation
induced by TLR agonist exposure results in activation of CD4+
CM and EM T cells to enter cell cycle and a heightened tendency
for the activated T cells to die. This is most apparent in the CD4
+
T cell population. Although these cells progress into S phase (not
shown), there is minimal evidence of complete cell division, as is
seen after TCR stimulation (Figure 5). Likewise, though
movement of cells into cell cycle is often associated with some
level of cell death, this is disproportionately increased in cells
activated in the presence of TLR agonists. Among CD8
+ T cells,
even though they are infrequently activated by TLR ligand
exposure to enter cell cycle, they also tend to become apoptotic
after activation, though less frequently than CD4
+ T cells do.
In summary, in vitro exposure of peripheral blood mononuclear
cells to a variety of microbial TLR agonists results in activation of
T cells predominantly of central memory and effector memory
phenotype. CD8+ EM cells are activated to express CD69 that
may promote their retention in secondary lymphoid tissues while
CD4+ CM and EM T cells are activated to enter cell cycle and to
die. We provide here an indication of how systemic exposure to
microbial TLR agonists that include both HIV RNAs and a
Figure 4. Toll-like receptors 3 and 5 are expressed by a subset of T cells, but expression is not always sufficient for activation by
TLR ligands. (A) Whole PBMCs were isolated from healthy donors and expression of TLRs 2, 3, and 5 were evaluated by flow cytometry on gated
CD3+ T cells. (B) Whole PBMCs, purified T cells (.95% CD3
+), or purified T cells separated from whole PBMCs by a transwell, were cultured in medium
alone, or in medium supplemented with plate bound anti-CD3, poly I:C or flagellin A. Expression of CD38 on memory (CD45RO
+CD45RA
2) CD4
+ T
cells was assessed by flow cytometry following overnight culture. Dotplots shown are representative of 8 separate experiments.
doi:10.1371/journal.pone.0001915.g004
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may drive T cell activation and cell death in chronic HIV
infection.
Materials and Methods
Subjects
These studies were approved by the Institutional Review Board
of University Hospitals/Case Medical Center. Blood samples were
obtained from 20 healthy donors.
Cells
Blood was collected in heparin-coated tubes and peripheral
blood mononuclear cells (PBMCs) were isolated by centrifugation
over Ficoll-Histopaque. The culture medium consisted of RPMI
1640 (Bio Whittaker, Walkersville, MD) supplemented with 50U/
ml penicillin, 50 mg/ml penicillin/streptomycin, 2mM L-gluta-
mine (Bio Whittaker) and either 10% fetal bovine serum (Gemini
Bioproducts, Woodland, CA) or 10% Human AB serum (Gemini
Bioproducts). Monocytes and T cells were negatively selected by
immunoaffinity using MACS isolation kits (Monocyte Isolation kit
II and the Pan T cell kit, respectively) (Miltenyi Biotec, Bergisch
Gladbach, Germany). Monocytes and T cells were evaluated for
purity based on CD14 or CD3 expression and were 85–90% and
95–98% pure, respectively. Transwell experiments were per-
formed using membrane inserts containing 0.4 mM pores (Corning
Incorporated, Corning, NY)
Cell culture
PBMCs were stimulated with plate bound-anti-CD3 monoclo-
nal antibodies (BD Pharmigen, San Diego, CA; 10 mg/ml) or TLR
ligands as indicated. Peptidoglycan (PGN, E. coli 2 mg/ml), a
synthetic analogue of double stranded RNA (Poly I:C 25 mg/ml),
lipopolysaccharide (E. coli, LPS 20ng/ml), flagellin (A from
Salmonella typhimurium, B from Bacillus Subtilis,1mg/ml), imiquimod
(5 mg/ml), single stranded Poly U complexed with the cationic
lipid Lyovec
R (ssPolyU 10 mg/ml) were acquired from Invivogen
San Diego CA), and unmethylated DNA (CPG 2395 3 mg/ml),
was obtained from Coley Pharmaeceuticals, Wellesley, MA).
Flow cytometric evaluation of T cell populations
Fluorochrome labeled monoclonal antibodies against CD3,
CD4, CD8, CD14, CD45RO, CD45RA, CCR7, CD38, CD69
HLA-DR, Ki-67 and labeled Annexin V were purchased from BD
Sciences/Pharmingen. Phycoerytherin conjugated antibodies to
TLR2 and TLR3 were obtained from eBioscience, (San Diego,
CA) and PE conjugated antibody to an intracellular portion of
TLR5 was obtained from Imgenex (San Diego, CA). Cells were
identified by forward and side scatter characteristics and were
analyzed by flow cytometry (LSR-II, Becton Dickinson, San Jose
Figure 5. Activation as a result of TLR ligand exposure preferentially induces T cell death especially among CD4+ T cells. PBMCs were
labeled with CFSE and incubated for 6 days in the presence of anti-CD3 antibody, medium alone or TLR ligands alone (PGN, poly-I:C, LPS (10 or 20 ng/
ml), Flagellin A, Flagellin B or imiquimod). After 6 days of incubation, the CD4
+ and CD8
+ T cells were examined for dilution of CFSE dye and for
binding of Annexin V. Numbers in right upper corners represent percentage of Annexin V-binding cells. Numbers in the left lower corner represent
percentage of cells that diluted dye without Annexin-V binding. This experiment is representative of three separate experiments.
doi:10.1371/journal.pone.0001915.g005
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before staining with anti-TLR antibodies.
Cell proliferation and death
PBMCs were suspended in PBS/0.3% BSA and were labeled
with 0.01 mM carboxy-fluorescein diacetate, succinimidyl esther
(CFSE, Invitrogen ,Oregon, USA) for 10 minutes at 37uC . Cold
fetal bovine serum (Gemini Bio-Products, Woodland,CA) was
added and cells were incubated for 5 minute on ice. Samples were
centrifuged and resuspended in complete medium and stimuli as
indicated. Following 7 days of culture, cells were stained for
identification of lymphocyte subsets as above; cellular proliferation
was monitored by dilution of CFSE dye and apoptotic cells were
identified by binding of PE-conjugated Annexin V (BD Biosci-
ences, San Diego,CA).
Statistical methods
Group means were compared for statistical significance by use
of a Wilcoxon rank test and a p-value of 0.05 was considered
nominally significant.
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